Findings

What do systematic reviews say?

1 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

Failure to induce remission at 6 weeks · Patients with active Crohn's disease

Two infusions of natalizumab (300 mg or 3 mg/kg) leads to lower failure to induce remission at 6 weeks compared with placebo (high certainty).

2 findings from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.85 [0.78, 0.93]
2 studies · 1034 participants
High
Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.85 [0.76, 0.95]
3 studies · 1543 participants
Moderate